Today: 20 July 2026
Experian share price: EXPN steadies after midweek slide as traders eye Feb dividend
25 January 2026
1 min read

Experian share price: EXPN steadies after midweek slide as traders eye Feb dividend

London, Jan 25, 2026, 08:48 GMT — Market closed

  • Experian shares ended the session at 3,029 pence, gaining 0.4%.
  • The stock remains down for the week following a steep fall right after the update.
  • Investors are focused on the dividend payment scheduled for Feb. 6 and the full-year results set for May 20.

Experian shares ended Friday at 3,029 pence, climbing 0.4% following a sharp midweek drop that pulled the UK credit data provider down from its recent peaks.

The bounce barely makes a dent. The stock remains roughly 8% below last Friday’s close as investors digest the latest trading update and its implications for lending-driven revenues and growth stocks amid volatile trading.

Monday’s tone owes a lot to the shift in sentiment. The FTSE 100 dropped 0.07% last week, ending a rally that lasted three weeks. Geopolitical tensions have crept back into focus.

Experian dropped a key update on Jan. 21, revealing that revenue for the quarter ending Dec. 31 climbed 12% at actual exchange rates, 10% on a constant currency basis, and 8% organically—that is, stripping out currency effects and acquisitions. CEO Brian Cassin said, “We delivered strong Q3 growth.” The company scheduled its full-year results for May 20. Experian

The market reaction was tougher than the headline figures suggested. Shares dropped 4.9% on Wednesday, then slipped another 1.8% on Thursday, putting them roughly 25% below their 52-week peak, according to MarketWatch data.

Jefferies analyst Allen Wells described the quarter as “in line with expectations,” highlighting solid underlying trends. He pointed to strength in the consumer business across North America and Latin America. Wells also confirmed the company’s FY26 margin outlook remains intact, forecasting a 30 to 50 basis-point improvement excluding currency effects; one basis point equals one-hundredth of a percentage point. Investing.com UK

Experian operates alongside Equifax and TransUnion in a sector deeply tied to credit checks and decisioning tools, where loan demand directly drives volume. Fraud and identity products offer some buffer during downturns, but they don’t fully make up for the boost a broad lending surge provides.

Income-focused investors have a nearer-term date to watch. Experian announced its first interim dividend at roughly 15.88 pence per share, with payment scheduled for Feb. 6.

The downside remains clear. If consumer and mortgage demand hold weak or macro pressures linger in higher-rate markets, bureau volumes could stay uneven, keeping the stock under pressure despite consistent execution.

Focus now turns to Monday’s reopening in London following the late-week halt. Key dates ahead include the dividend payout on Feb. 6 and the full-year results due May 20.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Chimeric Therapeutics (ASX:CHM) Jumps 9% as Investors Re-engage with Biotech
    July 20, 2026, 4:04 AM EDT. Chimeric Therapeutics Ltd (ASX:CHM) advanced 9.09% to end at AUD 0.048, valuing the company at about AUD 2.78 million. Despite a drop of more than 90% in the last year, the stock saw renewed buying activity. Trading volume was roughly AUD 15,203, signalling increasing interest across Australia's healthcare sector. The company is making headway with its cell therapy clinical programs focused on oncology, and clinical progress remains pivotal for market perception. Early-stage biotech names like CHM tend to post sharp moves in response to research breakthroughs and project updates, underscoring the industry's swings and focus on innovation.
Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Previous Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus
Next Story

Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus

Go toTop